Karim Salame, MD
Neuromuscular Medicine · Columbia, MONPI 1215190681
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (36.6%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 8 manufacturers reported payments, led by CSL Behring at 50.1% of the total.
Across 21 payments — averaging $190.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$2K
- Argenx US, Inc.$1K
- AstraZeneca$232
- Genentech USA, Inc.$146
- Biogen$134
- Teva Pharmaceuticals USA, Inc.$110
- plus $86 from 2 others
What the payments were for
- Consulting fees$1,18830%
- Travel & lodging$1,34033%
- Food & beverage$1,46937%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 9 | $2,009 |
| Argenx US, Inc. | 2 | $1,291 |
| AstraZeneca | 2 | $232 |
| Genentech USA, Inc. | 1 | $146 |
| Biogen | 1 | $134 |
| Teva Pharmaceuticals USA, Inc. | 1 | $110 |
| AbbVie | 4 | $74 |
| Impel Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few neuromuscular medicine providers in Missourito place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 26 | $260,111 |
| CuvitruImmun Glob G(Igg)/Gly/Iga Ov50 | 20 | $147,971 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 16 | $123,433 |
| Pyridostigmine Bromide | 55 | $4,608 |
| Mycophenolate Mofetil | 25 | $4,492 |
| Memantine Hcl | 60 | $3,853 |
| Quetiapine Fumarate | 14 | $1,079 |
| RivastigmineRivastigmine Tartrate | 15 | $940 |
| Duloxetine Hcl | 52 | $912 |
| Gabapentin | 62 | $737 |
| Levetiracetam | 29 | $684 |
| Donepezil Hcl | 66 | $666 |
| Carbamazepine | 12 | $587 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 54 | $492 |
| Prednisone | 64 | $399 |
Paid to pharmacies, not to this prescriber.
Other neuromuscular medicine in Columbia
- William ArnoldColumbia$42K
- Richard BarohnColumbia$11K
- Ryan CastoroColumbia$7K
- Erik EnsrudColumbia$5K
- Nesreen JaafarColumbia$255
- Melanie GlennColumbia$90
- Niranjan SinghSaint Louis$60K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.